Recurrent Glioblastomas
| Location: | Maryland |
|---|---|
| Posted: | Mar 31, 2026 |
| Due: | Apr 15, 2026 |
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | NIMH26000869 |
| Publication URL: | To access bid details, please log in. |
- Contract Opportunity Type: Special Notice (Original)
- Original Published Date: Mar 31, 2026 08:20 am EDT
- Original Response Date: Apr 15, 2026 12:00 pm EDT
- Inactive Policy: 15 days after response date
- Original Inactive Date: Apr 30, 2026
-
Initiative:
- None
- Original Set Aside: 8(a) Sole Source (FAR 19.8)
- Product Service Code: R499 - SUPPORT- PROFESSIONAL: OTHER
-
NAICS Code:
- 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
-
Place of Performance:
Bethesda , MD 20814USA
The goal of this clinical trial is to evaluate progression-free and overall survival in participants
with recurrent glioblastoma receiving LMP744 compared to historic controls. We will also
directly compare molecular and metabolic profiles of tissue, CSF, and plasma pre- and postexposure to LMP744 to determine pharmacologic responses to the drug in this patient
population. We will also correlate the pre- and post-exposure molecular and metabolic profiles
with clinical response and outcome, to determine which molecular and metabolic features are
predictive of drug response. The latter information will be critical for the design of phase III
clinical trials involving LMP744. Finally, we will evaluate the safety of LMP744 in patients with
recurrent glioblastoma through continuous, objective monitoring. This is the first clinical trial to investigate the role of the novel indenoisoquinolone, CMYC/TOPOISOMERASE 1 inhibitor LMP744 in participants diagnosed with recurrent glioblastoma. Results from this study will provide objective assessment of the pharmacologic response to the drug and provide an initial assessment of efficacy when compared to historical controls. Our goal is to addresses the urgent need for effective therapies for patients with recurrent glioblastoma. Clinical trial monitoring of each enrolled patient (40 total) will be required for accutae assessment of safety for enrolled patients and future patients on study.
- 3100 Center Drive Room 1B59
- Bethesda , MD 20892
- US
- Joseph Kennedy
- joseph.kennedy@nih.gov
- Mar 31, 2026 08:20 am EDTSpecial Notice (Original)
With GovernmentContracts, you can:
- Find more opportunities and win more business
- Receive daily alerts for all new bid opportunities
- Get contract opportunities matched to your business
See also
...Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood...- OTHER ...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 5/31/2029
...neuroimaging research by enabling high-quality imaging directly at the bedside. Unlike conventional high... ...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 6/09/2026
..., and tight-tolerance air temperature control systems for the conduct of research and ...
COMMERCE, DEPARTMENT OF
Bid Due: 6/12/2026
...beadchips will be implemented as part of a study conducted by the Center ...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 6/12/2026